Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine and risperidone in patients with schizophrenia, acute schizophrenia-like psychotic disorder, or schizoaffective disorder

Trial Profile

Olanzapine and risperidone in patients with schizophrenia, acute schizophrenia-like psychotic disorder, or schizoaffective disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Risperidone
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 24 Jul 2013 New trial record
    • 27 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top